Warning: session_start(): Cannot send session cookie - headers already sent by (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1

Warning: session_start(): Cannot send session cache limiter - headers already sent (output started at /home2/don/public_html/daily-enews-archives.php:5) in /home2/don/public_html/header08.php on line 1
OBR Daily - Our Oncology Focused E-News Service

Register for OBR daily



Warning: Missing argument 1 for showSidebarBanner(), called in /home2/don/public_html/sidebar_obrgreen.php on line 38 and defined in /home2/don/public_html/include/banners.php on line 243
KH_PatientWebinar_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

GERN $3.70 0.4500 +13.85%
GALE $2.07 0.2100 +11.29%
FATE $4.23 0.3800 +9.87%
PGNX $6.77 0.3500 +5.45%
NLNK $35.33 1.8100 +5.40%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

ARGS $8.50 -0.4100 -4.60%
EPZM $22.49 -1.0700 -4.54%
CLVS $48.60 -2.1900 -4.31%
CPXX $1.86 -0.0800 -4.12%
GALT $4.20 -0.1500 -3.45%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

Hopes for Single Blood Test to Detect Many Cancer Types

(PharmaTimes [UK]) Nov 2, 2014 - Scientists have identified more than 800 markers in the blood of cancer patients that could help lead to a single test for early detection.
read article 



Small Advantage for Radioiodine in Thyroid Ca

(MedPage Today) Oct 31, 2014 - Radioiodine therapy edged out no ablation in papillary thyroid cancer, researchers reported here.
read article (free registration required) 



Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(Yahoo! Finance) Nov 3, 2014 - Threshold Pharmaceuticals, Inc., today announced that its partner Merck KGaA, Darmstadt, Germany, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcinoma) study assessing the efficacy and safety of TH-302 in combination with gemcitabine in patients with previously untreated, locally advanced unresectable or metastatic pancreatic adenocarcinoma.
read article 



Viewing Cancer on the Move: New Device Yields Close-up Look at Metastasis

(John Hopkins University) Oct 30, 2014 - Johns Hopkins engineers have invented a lab device to give cancer researchers an unprecedented microscopic look at metastasis, the complex way that tumor cells spread through the body, causing more than 90 percent of cancer-related deaths.
read press release 



Effect of Chemotherapy on Surgical Resection of Liver Tumors

(CHLA) Oct 30, 2014 - A study of pediatric patients with hepatoblastoma led by researchers at Children's Hospital Los Angeles (CHLA) suggests an opportunity to reduce chemotherapy in up to 65 percent of patients, which could lead to a decrease in the incidence of adverse effects.
read press release 



Sea Sponge Drug Could Boost Advanced Breast Cancer Survival by Five Extra Months

(Cancer Research UK) Nov 3, 2014 - The cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
read press release 



Geron Announces Removal of Full Clinical Hold on Imetelstat IND

(NASDAQ) Nov 3, 2014 - Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on Geron's investigational new drug (IND) application for imetelstat.
read article 



Release of 2015 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System Final Rules

(ASCO in Action) Oct 31, 2014 - This afternoon, the Centers for Medicare & Medicaid Services (CMS) released its final rule on the 2015 Medicare Physician Fee Schedule.
read article 



Nurses to Hold Ebola Protests in 13 States

(The Hill) Oct 30, 2014 - The largest U.S. nurses union is planning a day of action in mid-November to protest the lack of federally enforced safety precautions against Ebola.
read article 



NIMH Creates New Unit to Support Its Research Domain Criteria Initiative

(NIH) Oct 31, 2014 - A new effort by the National Institutes of Health will facilitate communication among scientists, clinicians, and the public to reframe mental health research, from diagnosis to treatment.
read press release 



FDA Panel Backs Daiichi's Blood Thinner

(Reuters) Oct 30, 2014 - A panel of advisers to the U.S. Food and Drug Administration voted 9-1 in favor of approving Japanese drugmaker Daiichi Sankyo Co's blood clot and stroke preventer for use in some patients with atrial fibrillation.
read article 



Dr. James A. Tulsky Receives American Cancer Society Pathfinder in Palliative Care Award

(ACS) Oct 22, 2014 - James A. Tulsky, M.D., chief of Duke Palliative Care and professor of Medicine and Nursing at Duke University, has been named the 2014 recipient of the American Cancer Society Pathfinder in Palliative Care Award.
read press release 



ACCC Update

(ACCC) Oct 30, 2014 - The Association of Community Cancer Centers (ACCC) announces the departure of Matt Farber, MA, Director of Provider Economics and Public Policy.
read article 



Message to Pharma: Large Trials in Mesothelioma Are Possible

(The Meso Foundation blog) Oct 28, 2014 - This week, a notification was sent to investigators on the DETERMINE Trial that accrual will be completed by the end of October. DETERMINE is an international, randomized trial comparing treatment with an immunotherapy drug called tremelimumab to treatment with placebo as second or third line therapy in patients with malignant mesothelioma.
read article 



Living With Cancer: Not Talking About Medical Mistakes

(New York Times/Well blog) Oct 30, 2014 - Despite my best efforts, I remain bewildered about the surgical mishap I suffered in 2008. It was a debulking operation — the removal of all organs affected by a cancer that originated in my ovaries.
read article 



Look Here: Phone App Checks Photos For Eye Disease

(NPR/Shots blog) Oct 31, 2014 - Bryan Shaw showed it was possible to detect early signs of eye cancer from a family photo album. Now, he and his research team have made an iPhone app.
read article 



In Year Two, MD Anderson Moon Shots Program Begins to Spin Off Innovation

(MD Anderson) Oct 30, 2014 - Improved surgical outcomes for ovarian cancer, expanded potential impact for new drugs, and a novel family outreach program to head off cancers fueled by known genetic risk mutations are among the early innovations of The University of Texas MD Anderson Cancer Center’s Moon Shots Program.
read press release 



Billionaire Berg Funds New Prostate Test With Rent Earned From Apple

(BloombergBusinessweek) Oct 31, 2014 - Silicon Valley real estate billionaire Carl Berg thinks he’s found a better prostate cancer test and he’s investing hundreds of millions of dollars to bring it to market.
read article 



Onxeo S.A.: Positive Phase II Preliminary Results of Validive® For the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients

(Yahoo! Finance) Oct 30, 2014 - Onxeo S.A., an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, today announced positive preliminary top-line results from its Phase II clinical trial of Validive® (mucoadhesive buccal tablet MBT clonidine Lauriad®) for prevention of severe oral mucositis (OM).
read article 



Synthetic Lethality Offers a New Approach to Kill Tumor Cells, Explains Moffitt Cancer Center Researcher

(Moffitt Cancer Center) Oct 30, 2014 - The scientific community has made significant strides in recent years in identifying important genetic contributors to malignancy and developing therapeutic agents that target altered genes and proteins.
read press release 



Scientists Trigger Self-Destruct Switch in Lung Cancer Cells

(Cancer Research UK) Oct 31, 2014 - Cancer Research UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells - paving the way for new treatments, according to research that will be presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool next week.
read press release 



Potential Therapy For Postpartum Breast Cancer Investigated

(ResearchNews@Vanderbilt/Vanderbilt University) Oct 30, 2014 - Nearly 25 percent of all breast cancers among premenopausal women occur within two to five years following a pregnancy.
read article 



Scientists Pursue Novel Blood Tests For Cancer

(MIT Technology Review) Oct 31, 2014 - The inventor of a breakthrough DNA test for Down syndrome says the technology can be used to screen people for cancer.
read article 



Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy

(Astellas) Oct 30, 2014 - Medivation Inc. and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy.
read corporate press release 



NIMH Creates New Unit to Support Its Research Domain Criteria Initiative

(NIH) Oct 31, 2014 - A new effort by the National Institutes of Health will facilitate communication among scientists, clinicians, and the public to reframe mental health research, from diagnosis to treatment.
read press release